MedTrace Logo

Regorafenib Post-marketing Surveillance in Japan

NCT01933958 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 72

Last updated 2022-04-01

No results posted yet for this study

Summary

The objective of this study is to assess safety and effectiveness of Regorafenib using in real clinical practice

Conditions

Interventions

DRUG

Regorafenib (Stivarga, BAY73-4506)

The usual dosage is 160 mg of Regorafenib/ STIVARGA taken orally after meal once daily for 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks.

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-04
Primary Completion
2021-03-29
Completion
2021-10-29

Countries

  • Japan

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01933958 on ClinicalTrials.gov